Maraviroc - CAS 376348-65-1
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Maraviroc
Catalog Number:
B0084-067502
Synonyms:
4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl-d6)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; UK 427857-d6;
CAS Number:
376348-65-1
Description:
Selective CCR5 antagonist
Molecular Weight:
513.67
Molecular Formula:
C29H41F2N5O
Quantity:
Grams-Kilos
Quality Standard:
In-house
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
O=C(C1CCC(CC1)(F)F)N[C@H](c1ccccc1)CCN1C2CCC1CC(C2)n1c(C)nnc1C(C)C
InChI:
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
InChIKey:
GSNHKUDZZFZSJB-HLMSNRGBSA-N
Targets:
CCR | HIV
Catalog Number Size Price Stock Quantity
B0084-067502 50 mg $199 In stock
Bulk Inquiry
Chemical Structure
CAS 376348-65-1 Maraviroc

Related CCR Products


CAS 1416258-16-6 (±)-BI-D

(±)-BI-D
(CAS: 1416258-16-6)

Approximately 2.4–2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160–200 ...

CAS 624733-88-6 MK-0812

MK-0812
(CAS: 624733-88-6)

Potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes

CAS 701213-36-7 BMS-626529

BMS-626529
(CAS: 701213-36-7)

BMS-626529 is a member of the new drug class of HIV-1 attachment inhibitors currently in development. BMS-663068 is the phosphonooxymethyl prodrug of BMS-626529...

CAS 1262238-11-8 INCB3344

INCB3344
(CAS: 1262238-11-8)

A novel, potent and selective small molecule antagonist of the mouse CCR2 receptor

BMS-663749
(CAS: 864953-33-3)

BMS-663749 is HIV-1 attachment inhibitor.

CAS 159989-64-7 Nelfinavir

Nelfinavir
(CAS: 159989-64-7)

Nelfinavir is a HIV protease inhibitor; antiretroviral; and anti-tumor agent.

CAS 1051375-16-6 Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572)
(CAS: 1051375-16-6)

Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM, modest activity against raltegravir-resistant signature mutants Y1...

CAS 143491-57-0 Emtricitabine

Emtricitabine
(CAS: 143491-57-0)

Emtricitabine moderately reduces hepatocyte proliferation independent of effects on mtDNA in HepG2 human hepatoma cells.

CAS 874911-96-3 ZK 756326

ZK 756326
(CAS: 874911-96-3)

Selective, non-peptide CCR8 agonist

K-11777
(CAS: 233277-99-1)

K-11777 is a potent, irreversible cysteine protease inhibitor. Besides, K11777 is not only a substrate but also a mechanism-based inhibitor of CYP3A4.

CAS 247580-43-4 SB 328437

SB 328437
(CAS: 247580-43-4)

Potent and selective CCR3 antagonist

AZD-5672
(CAS: 780750-65-4)

AZD5672 is CCR5 receptor antagonist originated by AstraZeneca. In Jul 2009, Phase-II for Rheumatoid arthritis in USA was discontinued.

CP-481715
(CAS: 212790-31-3)

CP-481715 is a potent and selective CCR1 antagonist with >100-fold selective for CCR1 as compared with a panel of G-protein-coupled receptors including related ...

CAS 229975-97-7 Atazanavir Sulfate

Atazanavir Sulfate
(CAS: 229975-97-7)

Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM. It is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is ...

BMS-488043
(CAS: 452296-83-2)

BMS-488043 is a small-molecule HIV fusion inhibitor.

CAS 353791-85-2 J 113863

J 113863
(CAS: 353791-85-2)

Potent CCR1 antagonist

CAS 1155419-89-8 BI 224436

BI 224436
(CAS: 1155419-89-8)

BI 224436 is a novel HIV-1 non-catalytic-site integrase inhibitor; has antiviral EC50s of <15 nM against different HIV-1 laboratory strains and cellular cytotox...

CAS 544467-07-4 HIV-1 integrase inhibitor

HIV-1 integrase inhibitor
(CAS: 544467-07-4)

HIV-1 integrase inhibitor is uesful for anti-HIV, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other s...

NSC5844
(CAS: 140926-75-6)

A CCR1 agonist; A bisquinoline compound

CAS 887401-92-5 INCB 3284

INCB 3284
(CAS: 887401-92-5)

Potent, selective and orally bioavailable CCR2 antagonist with IC50 of 3.7 nM

Reference Reading


1.Maraviroc, as a switch option, in HIV-1 infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first N(t)RTI+PI/r regimen. Week 48 results of the randomised, multicentre MARaviroc switCH study (MARCH).
Pett SL1, Amin J2, Horban A3, Andrade-Villanueva J4, Losso M5, Porteiro N6, Sierra Madero J7, Belloso W8, Tu E2, Silk D2, Kelleher A9, Harrigan R10, Clark A11, Sugiura W12, Wolff M13, Gill J14, Gatell J15, Fisher M16, Clarke A16, Ruxrungtham K17, Prazuck Clin Infect Dis. 2016 Apr 5. pii: ciw207. [Epub ahead of print]
BACKGROUND:  Alternative combination antiretroviral therapies in virologically suppressed HIV-infected patients experiencing side-effects and/or at ongoing risk of important co-morbidities from current therapy are needed. Maraviroc(MVC), a chemokine receptor-5(CCR5) antagonist, is a potential alternative component of therapy in those with R5-tropic virus.
2.Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc.
Ball C1, Chou SF1, Jiang Y1, Woodrow KA2. Mater Sci Eng C Mater Biol Appl. 2016 Jun 1;63:117-24. doi: 10.1016/j.msec.2016.02.018. Epub 2016 Feb 4.
Electrospun fibers show potential as a topical delivery system for vaginal microbicides. Previous reports have demonstrated delivery of anti-HIV and anti-STI (sexually transmitted infection) agents from fibers formulated using hydrophilic, hydrophobic, or pH-responsive polymers that result in rapid, prolonged, or stimuli-responsive release, respectively. However, coaxial electrospun fibers have yet to be evaluated as a highly tunable microbicide delivery vehicle. In this research, we explored the opportunities and limitations of a model coaxial electrospun fiber system to provide broad and tunable release rates for the HIV entry inhibitor maraviroc. Specifically, we prepared ethyl cellulose (EC)-shell and polyvinylpyrrolidone (PVP)-core fibers that were capable of releasing actives over a range of hours to several days. We further demonstrated simple and effective methods for combining core-shell fibers with rapid-release formulations to provide combined instantaneous and sustained maraviroc release.
3.The CD4/CD8 ratio is inversely associated with cIMT progression in HIV infected patients on antiretroviral treatment.
Bernal Morell E1, Serrano Cabeza J2, Muñoz A3, Marín I4, Masia M5, Gutierrez F6, Cano A7. AIDS Res Hum Retroviruses. 2016 Mar 22. [Epub ahead of print]
Inversion of the CD4/CD8 ratio (< 1) has been identified as a surrogate marker of immunosenescence, and an independent predictor of AIDS events in HIV infected patients and mortality in the general population. We aimed to assess the association between the CD4/CD8 ratio and carotid intima-media thickness (cIMT) progression in treated HIV-infected patients as a marker of coronary heart disease. A longitudinal study was conducted during three years in 96 virally suppressed HIV infected patients receiving antiretroviral treatment (ART). We analyzed the associations between the CD4/CD8 ratio, cardiovascular risk factors and antiretroviral treatment (ARV), and progression of subclinical atherosclerosis assessed using carotid cIMT at baseline and after three years. Finally, ninety-six patients completed the study. Seventy six (79.1%) patients were male, aged 44±10 years, 39 (40.6%) were on treatment with protease inhibitors; 49 (51.04%) with non-nucleoside reverse transcriptase inhibitors (NNRTI), 6 (6.
4.Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies.
Piotrowska A1, Kwiatkowski K1, Rojewska E1, Makuch W1, Mika J2. Neuropharmacology. 2016 Apr 23. pii: S0028-3908(16)30164-2. doi: 10.1016/j.neuropharm.2016.04.024. [Epub ahead of print]
Recent studies suggest that CCR5 and its ligands are important regulators for the development of neuropathic pain and that their modulation can have some beneficial properties. Therefore, the aim of our study was to investigate the influence of maraviroc (MVC, a CCR5 antagonist) on glial polarization markers and intracellular signaling pathways in the spinal cord 7 days after chronic constriction injury (CCI) to the sciatic nerve and in primary glial cultures after LPS stimulation. Our results demonstrated that chronic intrathecal administration of MVC diminished neuropathic pain symptoms and nociceptive threshold ∼60 min after drug administration on days 3 and 7 post-CCI. MVC downregulated the levels of phosphorylated p38 MAPK, ERK1/2 and NF-κB proteins in the spinal cord and upregulated STAT3 in the dorsal root ganglia (DRG). Additionally, using Western blot analysis, we demonstrated that MVC effectively diminished "classical" activation markers: IL-1β, IL-18, IL-6 and NOS2 in the spinal cord.